Empagliflozin is not recommended for patients with severe renal impairment, end-stage renal disease, or those receiving dialysis because its effectiveness relies on the kidneys' ability to filter glucose from the blood
Research is needed to help illustrate the size and nature of access gaps so that we can design better coverage policies. Ultimately, there is a need for policymakers to recognize that factors unrelated to whether an individual has a medical necessity for treatment can affect whether or not a person is likely to receive these medications, says study lead author Meghan Podolsky (SPH24), research fellow in the Department of Global Health and an SPH alum who completed the MS program in epidemiology last year
After Dose Increases Each dose increase can trigger a renewed response as the body adapts to stronger appetite suppression
Juvederm Voluma is FDA-approved and treatment generally takes an hour or less
Chemical Resolution Industrial production of R-ALA primarily relies on the chemical resolution of racemic ALA using chiral resolving agents
Any symptoms suggestive of blood clots, as described previously, warrant immediate medical assessment
